Curetis OpGen Q1 Revenues Rise 34 Percent on Combination With Curetis OpGen said it is awaiting a clearance decision for its Unyvero pneumonia cartridge in China, where it is currently under review and pending approval. OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators. OpGen Posts 70 Percent Increase in Q3 Revenues Amid Shuffling of Portfolio The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line. Multiplex PCR Panels for Joint Infections on the Horizon Premium BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development. OpGen Posts 54 Percent Increase in Preliminary Q3 Revenues, Consolidates Product Portfolio Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations. Sep 30, 2020 Curetis Receives €350K German Government Grant to Develop Carbapenem Resistance Test Aug 20, 2020 OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit Aug 12, 2020 OpGen Q2 Revenues Climb 20 Percent Jul 9, 2020 Curetis Gains Access to Additional €5 Million Debt Financing for COVID-19 R&D May 7, 2020 OpGen Q1 Revenues Drop 38 Percent Apr 21, 2020 Curetis, Karolinska Institute Collaborate to Identify Bacterial Co-Infections in COVID-19 Patients Apr 14, 2020 OpGen Q1 Preliminary Revenues Down 38 Percent Mar 24, 2020 OpGen Fourth Quarter Revenues Increase 8 Percent Feb 20, 2020 Curetis Preliminary 2019 Revenues Up 64 Percent Feb 12, 2020 OpGen Preliminary 2019 Revenues up 19 Percent Feb 6, 2020 Curetis Signs Vietnam Distribution Deal for Unyvero Dx System, Cartridges Jan 30, 2020 Ares Genetics Collaborates With BGI on Coronavirus Testing in Europe Dec 20, 2019 FDA Clears Curetis Lower Respiratory Tract Infections Panel Nov 25, 2019 Curetis Reports 17 Percent Revenue Increase for First Nine Months of 2019 Nov 14, 2019 Curetis Posts 17 Percent Increase in Preliminary Revenues for First Nine Months of 2019 Nov 6, 2019 OpGen Posts 17 Percent Increase in Q3 Revenues Oct 24, 2019 OpGen Prices $9.4M Stock, Warrant Offering Oct 15, 2019 OpGen Plans $10.4M Stock, Warrant Sale Sep 18, 2019 Curetis Reports 36 Percent Increase in H1 Revenues Sep 4, 2019 OpGen, Curetis Enter Merger Agreement Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.